CorMedix (CRMD) EBIT (2010 - 2025)

CorMedix has disclosed EBIT across 16 years of filings, most recently posting -$59.5 million for Q4 2025.

• EBIT for Q4 2025 came in at -$59.5 million, down 290.53% year-over-year; the trailing twelve-month figure through Dec 2025 was $31.5 million (up 876.32% YoY), and the FY2025 annual result was $31.5 million, up 876.32% from the prior year.
• EBIT came in at -$59.5 million for Q4 2025 at CorMedix, down from $51.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $51.3 million in Q3 2025 to a low of -$59.5 million in Q4 2025.
• The 5-year median for EBIT is -$8.0 million (2021), against an average of -$4.1 million.
• Peak annual rise in EBIT reached 1661.93% in 2025, while the deepest fall reached 290.53% in 2025.
• CorMedix's EBIT stood at -$7.8 million in 2021, then declined by 7.83% to -$8.4 million in 2022, then tumbled by 86.77% to -$15.7 million in 2023, then jumped by 299.34% to $31.2 million in 2024, then tumbled by 290.53% to -$59.5 million in 2025.
• The last three EBIT figures came in at -$59.5 million (Q4 2025), $51.3 million (Q3 2025), and $19.5 million (Q2 2025), per Business Quant data.